Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Melanoma

This post hoc subgroup analysis examines the results of 3 randomized clinical trials to assess the association of BRAF V600E/K mutation status and previous BRAF inhibitor and MEK inhibitor therapy with response to treatment with pembrolizumab in patients with advanced melanoma.

Read the full article here

Related Articles